anti-IFN-alpha Human ELISA

Notice

Restriction of a minimal quantity of 5 kits per order may apply.

Research topic

Autoimmunity, Cytokines and Chemokines and related molecules, Growth hormone and factor-related products, Infection and inflammation

Storage/Shipping

2–8°C

Assay format

Sandwich ELISA, HRP-labelled antibody

Sample requirements

20 µl

Applications

Cell culture supernatant, Plasma, Serum, Urine

Calibration range

3.2  – 200 ng/ml

Limit of detection

1.38 ng/ml

Intra-assay

CV = 3.3%

Inter-assay

CV = 4.1%

Spiking Recovery

92%

Dilution Linearity

104 %

References to summary

• Middelhoff G, Boll I. A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia. Ann Hematol. 1992 May;64 (5):207-9
• Craxi A, Di Marco V, Volpes R, Palazzo U. Anti-alpha interferon antibodies after alpha interferon treatment in patients with chronic viral hepatitis. Hepatogastroenterology. 1988 Dec;35 (6):304-5
• Aitchison R, Allen P, Schey S, Newland AC. Anti-interferon antibodies in alpha interferon treated patients with chronic myeloid leukaemia. Br J Haematol. 1991 Jul;78 (3):465-7
• Figlin RA, Itri LM. Anti-interferon antibodies: a perspective. Semin Hematol. 1988 Jul;25 (3 Suppl 3):9-15
• Jacobs SL, Kelsey DK. Antibodies in patients with hairy-cell leukemia receiving alpha-2b interferon. N Engl J Med. 1986 Nov 27;315 (22):1418
• Thurmond LM, Brand CM, Leventhal BG, Finter NB, Johnston JM. Antibodies in patients with recurrent respiratory papillomatosis treated with lymphoblastoid interferon. J Lab Clin Med. 1991 Sep;118 (3):232-40
• Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol. 1985 Nov;3 (11):1522-8
• Bendtzen K, Svenson M, Jonsson V, Hippe E. Autoantibodies to cytokines--friends or foes?. Immunol Today. 1990 May;11 (5):167-9
• Pozzetto B, Mogensen KE, Tovey MG, Gresser I. Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J Infect Dis. 1984 Nov;150 (5):707-13
• von Wussow P, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H. Clinical significance of anti-IFN-alpha antibody titres during interferon therapy. Lancet. 1987 Sep 12;2 (8559):635-6
• Oberg K, Alm GV. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors. J Interferon Res. 1989 Sep;9 Suppl 1:S45-9
• Dummer R, Muller W, Nestle F, Wiede J, Dues J, Lechner W, Haubitz I, Wolf W, Bill E, Burg G. Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients. Cancer. 1991 May 1;67 (9):2300-4
• von Wussow P, Freund M, Dahle S, Jakschies D, Poliwode H, Deicher H. Immunogenicity of different types of interferons in the treatment of hairy-cell leukemia. N Engl J Med. 1988 Nov 3;319 (18):1226-7
• Levy-Koenig RE, Mundy MJ, Paucker K. Immunology of interferons. I. Immune response to protective and nonprotective interferons. J Immunol. 1970 Apr;104 (4):785-90
• Itri LM, Sherman MI, Palleroni AV, Evans LM, Tran LL, Campion M, Chizzonite R. Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-alpha 2a. J Interferon Res. 1989 Sep;9 Suppl 1:S9-15
• Porres JC, Carreno V, Ruiz M, Marron JA, Bartolome J. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatol. 1989 May;8 (3):351-7
• Prummer O. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group. Cancer. 1993 Mar 1;71 (5):1828-34
• de Wit R, Bakker PJ, Danner SA, Goudsmit J, Veenhof KH. Low incidence of anti-interferon-alpha antibodies in patients treated with interferon-alpha-2a for AIDS-associated Kaposi's sarcoma. Int J STD AIDS. 1990 Jul;1 (4):256-8
• Steinmann GG, God B, Rosenkaimer F, Adolf G, Bidlingmaier G, Fruhbeis B, Lamche H, Lindner J, Patzelt E, Schmahling C, et al.. Low incidence of antibody formation due to long-term interferon-alpha 2c treatment of cancer patients. Clin Investig. 1992 Feb;70 (2):136-41
• Spiegel RJ, Spicehandler JR, Jacobs SL, Oden EM. Low incidence of serum neutralizing factors in patients receiving recombinant alfa-2b interferon (Intron A). Am J Med. 1986 Feb;80 (2):223-8
• Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, Angarano G, Dianzani F, Pastore G. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver. 1993 Jun;13 (3):146-50
• Ichimura H, Shimase K, Tamura I, Kaneto E, Kurimura O, Aramitsu Y, Kurimura T. Neutralizing antibody and interferon-alpha in cerebrospinal fluids and sera of acute aseptic meningitis. J Med Virol. 1985 Mar;15 (3):231-7
• Mogensen KE, Daubas P, Gresser I, Sereni D, Varet B. Patient with circulating antibodies to alpha-interferon. Lancet. 1981 Nov 28;2 (8257):1227-8
• von Wussow P, Jakschies D, Hartung K, Deicher H. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol Int. 1988;8 (5):225-30
• Freund M, von Wussow P, Diedrich H, Eisert R, Link H, Wilke H, Buchholz F, LeBlanc S, Fonatsch C, Deicher H, et al.. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol. 1989 Jul;72 (3):350-6
• Figlin RA, deKernion JB, Mukamel E, Palleroni AV, Itri LM, Sarna GP. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. J Clin Oncol. 1988 Oct;6 (10):1604-10
• Gutterman JU, Fine S, Quesada J, Horning SJ, Levine JF, Alexanian R, Bernhardt L, Kramer M, Spiegel H, Colburn W, Trown P, Merigan T, Dziewanowski Z. Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Ann Intern Med. 1982 May;96 (5):549-56
• Antonelli G, Currenti M, Turriziani O, Riva E, Dianzani F. Relative frequency of nonneutralizing antibodies to interferon (IFN) in hepatitis patients treated with different IFN-alpha preparations. J Infect Dis. 1992 Mar;165 (3):593-4
• Steis RG, Smith JW 2nd, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med. 1988 Jun 2;318 (22):1409-13
• Gugliotta L, Catani L, Vianelli N, Mattioli Belmonte M, Cascione ML, Bendani M, Fanin R, Michieli MG, Baccarani M, Tura S. [Essential thrombocythemia: therapy with alpha interferons]. Haematologica. 1991 Jun;76 Suppl 3:374-7
• Faradzhev ZG, Samsonov VA, Parfenova TM, Malinovskaia VV. [The interferon status of patients with lymphoproliferative diseases of the skin and Kaposi's sarcoma]. Vestn Dermatol Venerol. 1990; (7):4-7